Read Time: 2 mins

54/Radiofrequency ablation of the diseased human left ventricle: biophysical and electrogram based analysis

Copy Link
Published Online: Oct 9th 2012 European Journal of Arrhythmia & Electrophysiology. 2022;8(Suppl. 1):abstr54
Authors: AP Bates (Presenting Author) – Cardiology Department, University Hospital Southampton, Southampton; JR Paisey – Cardiology Department, University Hospital Southampton, Southampton; AM Yue – Cardiology Department, University Hospital Southampton, Southampton; P Banks – Cardiology Department, University Hospital Southampton, Southampton; PR Roberts – Cardiology Department, University Hospital Southampton, Southampton; W Ullah – Cardiology Department, University Hospital Southampton, Southampton
Quick Links:
Article Information

Background: Predictors of effective ablation lesion delivery in the human left ventricle are not established, particularly in scar. Impedance drop and electrogram (EGM) attenuation are potential surrogates to assess this.

Objectives: Establish the relationships between Ablation Index (AI) and Force Time Integral (FTI) with impedance drop and EGM attenuation in the human left ventricle.

Methods: Patients undergoing ventricular tachycardia (VT) ablation were recruited. Mapping and ablation were performed using the Pentaray catheter twinned with Carto3 and the SmartTouch Surround Flow catheter respectively. Only endocardial lesions were considered. EGMs were collected pre- and post-ablation, with impedance, AI and FTI measured during. Percentage impedance drop was used to minimise the effect of starting impedance. Based on pre-ablation bipolar voltage, myocardium was adjudged low (LVM, <0.50 mV), intermediate (IVM, 0.51–1.50 mV) and normal voltage (NVM, >1.50 mV). To establish a parameter predicting lesion completion, the point where further ablation provided little change in biophysical measurements as a surrogate for thermodynamic equilibrium was sought, this being the beginning of the plateau in the impedance drop and AI/FTI relationships. Best fit curves were applied to the datasets, formulae established and the plateau determined as an impedance drop of 0.25% over 100 gs/100 AI. To assess the predictability of AI or FTI upon percentage impedance drop, linear regression was performed from the start of ablation to the calculated plateau points, also including in the model: catheter drift, orientation and endocardial voltage category.

Results: A total of 402 ablations were analysed in 15 patients. Percentage impedance drop correlated with AI and FTI (p<0.0005, Spearman’s Rho 0.52 both) plateauing at 763 AI and 713 gs, an impedance drop of 7.5%. Shallower curves occurred progressively from NVM to LVM (p<0.0005, Figure 1), alongside lower plateau points (NVM 853 AI/1007 gs at 10% drop; IVM 769 AI/761 gs at 8% drop; LVM 762 AI/540 gs at 6% drop). AI and FTI were both reasonably predictive of impedance drop (adjusted R2: 0.56 and 0.46), with this relationship weakening with increased scar (adjusted R2: AI–NVM 0.59, IVM 0.52, LVM 0.49; FTI–NVM 0.53, IVM 0.45, LVM 0.35). Bipolar EGMs attenuated with ablation (median pre-ablation 0.54 mV [0.29–0.98 mV], post-ablation 0.37 mV [0.20–0.56 mV], median attenuation 29.3% [4.4%–53.3%]; p<0.0005). Unipolar EGMs also attenuated with ablation (median pre-ablation 3.71 mV [2.36–5.40 mV], post-ablation 3.11 mV [2.09–4.65 mV], median attenuation 9.48% [3.15–23.14%]). Attenuation did not correlate with AI or FTI achieved for either bipolar or unipolar EGMs.

Conclusions: On biophysical analysis, an average ablation beyond AI of 763 and FTI of 713 gs offered little additional efficacy. Increasing scar blunted ablation efficacy and reduced the predictability of ablation. AI had a stronger relationship with impedance drop than FTI. EGM attenuation did not correlate with commonly used ablation parameters, suggesting it is a suboptimal surrogate for ablation lesion progression.

Further Resources

Share this Article
Related Content In Arrhythmia
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72